The Medication Gap in Workplace Heat Safety: A Q&A for Occupational Health Programs

Most workplace heat illness prevention programs treat all workers as physiologically equivalent. They aren't. A growing percentage of the U.S. workforce takes medications that meaningfully alter how the body handles heat, and almost no occupational heat program currently accounts for this. Closing this gap is one of the highest-leverage moves available in workplace heat safety.

This Q&A is for occupational health professionals, safety managers, and HR leaders responsible for heat illness prevention.

Q: How widespread is this issue?

More than most safety programs assume. Roughly two-thirds of U.S. adults take at least one prescription medication, and the percentage rises sharply with age. Among workers over 50, the proportion taking medications that affect thermoregulation, hydration, or cardiovascular response to heat is substantial. Some of these medications are obvious (diuretics for hypertension). Others are not (anticholinergic effects of common over-the-counter sleep aids and allergy medications).

In a typical workforce with average age and health profile, a meaningful fraction of workers carry medication-related heat vulnerability that isn't reflected in their standard safety profile.

Q: What's the strongest evidence on which medications matter?

A 2024 systematic review and meta-analysis published in eClinicalMedicine pooled data across dozens of trials on medication effects on core temperature during heat stress. The findings are the most rigorous evidence available, and they point to several drug classes with confirmed thermoregulatory impairment:

Strong anticholinergics (oxybutynin, benztropine, atropine, and the anticholinergic activity of many older antihistamines and tricyclic antidepressants). These reduce sweat production by blocking acetylcholine at sweat glands. Pooled data shows core temperature elevations of approximately 0.42°C at warm temperatures.
Non-selective beta-blockers (propranolol, nadolol, timolol). These cause peripheral vasoconstriction that impairs heat dissipation through the skin. Effect: about 0.11°C core temperature elevation. Notably, selective beta-blockers like metoprolol showed no significant effect.
Anti-Parkinson agents (levodopa, bromocriptine). Dopaminergic effects on central thermoregulation. Effect: about 0.13°C.
Sympathomimetics (epinephrine and similar). Increased metabolic heat production. Effect: about 0.41°C.

These are the medications with the clearest evidence of direct core temperature elevation during heat stress.

Q: What about diuretics? They're everywhere in older worker populations.

Diuretics affect heat tolerance through volume depletion rather than direct thermoregulatory disruption. They can reduce blood volume by up to 20%, which compromises plasma volume, stroke volume, and the cardiovascular response to heat. The 2024 meta-analysis found limited direct evidence of altered core temperature from diuretics specifically, but the volume effects are real and clinically meaningful, especially for workers also doing physical labor in heat.

Q: SSRIs and antidepressants?

The evidence is more ambiguous. SSRIs and SNRIs can alter sweat response (sometimes increasing it, sometimes decreasing it, depending on the specific drug). Direct core temperature effects at therapeutic doses haven't been clearly established in pooled analysis. The practical consideration: workers on these medications may show atypical sweat patterns, which can confuse standard heat illness recognition.

Q: ADHD medications?

Stimulants (methylphenidate, amphetamine-based medications) increase metabolic rate and can produce vasoconstriction. The theoretical risk in heat is real, and stimulant use is rising in working-age adults, but heat-specific evidence remains thinner than for the four classes above.

Q: How should occupational health programs use this information?

Three operational changes:

Build medication review into the heat-relevant intake process. This doesn't mean turning safety programs into medical reviews. It means asking whether workers are taking medications in the high-risk classes, treating that information confidentially, and using it to inform individualized monitoring rather than to exclude workers from work.
Develop tiered acclimatization protocols. The standard NIOSH-recommended progressive ramp (20% workload Day 1, increasing to full duty by Day 5) is appropriate for most workers but may need modification for workers on heat-sensitive medications. Slower ramps, lower target intensities, more frequent rest, and closer monitoring during the acclimatization window can meaningfully reduce risk without preventing the worker from doing the job.
Train supervisors and occupational health staff to recognize that workers on these medications may not present with textbook heat illness symptoms. Anticholinergic effects, for example, can mask the early warning of profuse sweating and produce a worker who is overheating without the visible cue that supervisors are trained to watch for.

Q: Isn't this a medical decision, not an occupational health decision?

Both. The decision about whether a worker takes a particular medication is clinical and belongs to the worker and their prescribing physician. The decision about how to structure work in heat for someone on that medication is an occupational health decision. The two need to be integrated, and currently they almost never are.

The solution isn't telling workers to stop their medications. The solution is building work environments and protocols that account for the medications they're taking.

Q: What about ADA implications?

The ADA framework requires reasonable accommodation for workers with disabilities, and many of the conditions treated by heat-sensitive medications qualify. The legal posture is well established: employers can ask about medical conditions in narrow contexts related to job function, must keep medical information confidential, and must provide reasonable accommodations.

In practice, a thoughtful occupational health program asks workers in high-heat-exposure roles about heat-sensitive medications as part of fitness-for-duty assessment, treats the information confidentially, and uses it to design protective protocols. This is consistent with ADA compliance and represents better practice than the current default of ignoring the issue entirely.

Q: Where does this fit relative to OSHA guidance?

OSHA's general duty clause and emerging heat standard discussions both presume that employers will take reasonable steps to protect workers from recognized hazards. Medication-related heat vulnerability is increasingly a recognized hazard in the scientific literature, even if it hasn't been explicitly incorporated into regulatory text. Programs that address it proactively are aligned with the direction of regulatory expectations and well-positioned for future requirements.

Q: What's the most important first step for an organization that hasn't addressed this?

Audit your current heat illness prevention program for any reference to medications. If the only mention is a vague line about "certain medications may increase heat risk," you have the gap most programs have. The first move is partnering with occupational health and clinical pharmacy resources to build a meaningful medication-aware layer into your existing program. You don't need to redesign the entire program. You need to add the missing component.

The short version: A meaningful percentage of workers take medications that alter heat tolerance, the strongest evidence points to four drug classes with confirmed thermoregulatory impairment, and almost no current workplace heat program accounts for this. Closing the gap requires medication-aware intake, tiered acclimatization protocols for higher-risk workers, supervisor training in atypical heat illness presentation, and integration between occupational health and clinical resources. The data supporting the need is stronger than the practice. That gap is the opportunity.

Desert Heat Consulting helps organizations integrate medication-aware risk assessment into workplace heat illness prevention programs. [Schedule a consultation.]